MSF Field Research > 1 Published Research and Commentary > TB > Moxifloxacin for tuberculosis - Authors' reply.

Please use this identifier to cite or link to this item:     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Download this article:
View/Open File Description Size Format
1203_Cox_Moxifloxacin-for-tuberculosis-Authors-reply_Lancet-12-177.pdfMain article45KbAdobe PDF

Title: Moxifloxacin for tuberculosis - Authors' reply.
Authors: Cox, Helen
Ford, Nathan
von Schoen-Angerer, Tido
Affiliation: Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa; University of Cape Town, Cape Town, South Africa; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerland
Citation: Lancet 2012; 12:177
Publisher: Elsevier
Journal: The Lancet Infectious Diseases
Issue Date: Mar-2012
DOI: 10.1016/S1473-3099(12)70015-4
PubMed ID: 22361421
Additional Links:
Type: Article
Language: en
MeSH: Tuberculosis
Tuberculosis, Multidrug-Resistant
ISSN: 1474-4457
Rights: Published by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see for further relevant comment.
Appears in topics: TB

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.


OR Logo Powered by Open Repository | Cookies


MSF logo MSF Field Research

Sep 5, 2015